Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m)

High Altitude Medicine and Biology

Volumn 6, Issue 2, 2005, Pages 158-166

  Pesce, Carlos ^a,b   Leal, Conxita ^c   Pinto, Hernán ^a   González, Gabriela ^a   Maggiorini, Marco ^d   Schneider, Michael ^e   Bärtsch, Peter ^e  

^a Sociedad Argentina de Medicina de Montaña   (Argentina)

^b DEPARTAMENTO DE CIENCIAS NATURALES Y ANTROPOLOGÍA   (Argentina)

^c Inst d'Estudis de Med de Muntanya   (Spain)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

AMS predictors; Ascent modality; Expedition style mountaineering; High altitude experience; Summiting; Susceptibility

Indexed keywords

ACETAZOLAMIDE; ANALGESIC AGENT; GLUCOCORTICOID;

ACUTE DISEASE; ADULT; ALTITUDE DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; FEMALE; FREQUENCY ANALYSIS; HUMAN; MALE; MOUNTAINEERING; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SELF EVALUATION; SEX DIFFERENCE; SYMPTOMATOLOGY;

ACCLIMATIZATION; ACUTE DISEASE; ADULT; ALTITUDE SICKNESS; ARGENTINA; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOUNTAINEERING; ODDS RATIO; PREVALENCE; QUESTIONNAIRES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 25844496907     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2005.6.158     Document Type: Article

References (20)

1. Bärtsch P., Müller A., Hofstetter D., Maggiorini M., Vock P., and Oelz O. (1993). AMS and HAPE scoring in the Alps. In: Hypoxia and Molecular Medicine, J.R. Sutton, C.S. Houston, and G. Coates, eds. Burlington, VT: Queen City Press, pp. 265-271.
2. Basnyat B., Gertsch J.H., Johnson E.W., Castro-Marin F., Inoue Y., and Yeh C. (2003). Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt. Med. Biol. 4:45-52.
3. Basnyat B., and Murdoch D.R. (2003). High-altitude illness. Lancet. 361:1967-1974.
4. Forster P. (1984). Reproducibility of individual response to exposure to high altitude. Br. Med. J. 289:1269.
5. Gertsch J.H., Basnyat B., Johnson E.W., Onopa J., and Holck P.S. (2004). Randomised, controlled trial of Ginkgo biloba and acetazolamide for prevention of acute mountain sickness: the prevention of high altitude illness trial (PHAIT). Br. Med. J. 328:797-799.
6. Hackett P.H., and Rennie D. (1978). Avoiding mountain sickness. Lancet. II:938.
7. Hackett P.H., Rennie D., and Levine H.D. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. II:1149-1154.
8. Hackett P.H., and Roach R.C. (2001). High-altitude illness. N. Engl. J. Med. 345:107-114.
9. Honigman B., Theis M.K., Koziol-McLain J., Roach R., Yip R., Houston C., and Moore L. (1993). Acute mountain sickness in general tourist population at moderate altitudes. Ann. Intern. Med. 118:587-592.
10. Kayser B. (1991). Acute mountain sickness in western tourists around the Thorong pass (5400 m) in Nepal. J. Wilderness Med. 2:110-117.
11. Maggiorini M., Bühler B., Walter M.K., and Oelz O. (1990). Prevalence of acute mountain sickness in the Swiss Alps. Br. J. Med. 261:853-855.
12. Maggiorini M., Müller A., Hofstetter D., Bärtsch P., and Oelz O. (1998). Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat. Space Environ. Med. 69:1186-1192.
13. Murdoch D.R. (1995). Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat. Space Environ. Med. 66:148-151.
14. Murdoch, D.R. (1999). How fast is too fast? Attempts to define a recommended ascent rate to prevent acute mountain sickness. Intern. Soc. Mountain Med. Newsletter. 9:3-6.
15. Pollard A., and Clarke C. (1988). Deaths during mountaineering at extreme altitude. Lancet. I:1277.
16. Richalet J.P., Keromes A., Dersch B., Corizzi F., Mehdioui H., Pophillat B., et al. (1988). Caractéristiques physiologiques des alpinistes de haute altitude. Sci. Sports. 3:89-108.
17. Roach R.C., Bärtsch P., Hackett P.H., and Oelz O. (1993). The Lake Louise acute mountain sickness scoring system. In: Hypoxia and Molecular Medicine. J.R. Sutton, C.S. Houston, G. Coates, eds. Burlington, VT: Queen City Printers, pp. 272-274.
18. Sampson J.B., Cymerman A., Burse R.L., Maher J.T., and Rock P.B. (1983). Procedures for the measurement of acute mountain sickness. Aviat. Space Environ. Med. 54:1063-1073.
19. Schneider M., Bernasch D., Weymann J., Holle R., and Bärtsch P. (2002). Acute mountain sickness: influence of susceptibility, pre-exposure and ascent rate. Med. Sci. Sport Exec. 34:1886-1891.
20. Wilson T.M., and Tanaka H. (2000). Meta-analysis of the age-associated decline in maximal aerobic capacity in men: relation to training status. Am. J. Physiol. Heart Circ. Physiol. 278:H829-H834.